Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Mechanisms behind the loss of BCMA in multiple myeloma & options for patients

Adam Sperling • 27 Sep 2023
IMS 2023
Multiple Myeloma Antibodies CAR-T Cevostamab Talquetamab

Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses how the loss of BCMA can occur in patients with multiple myeloma, and further highlights treatment options available when this occurs, including GPRC5D- and FcRH5-targeting agents. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting: Novartis, Roche

More from Adam Sperling

1:58
Clonal hematopoiesis in multiple myeloma and implications for therapy
Adam Sperling • 27 Sep 2023
2:05
Novel CAR-T constructs being explored in myeloma: T-Charge platform
Adam Sperling • 27 Sep 2023
1:53
PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myeloma
Adam Sperling • 4 Jun 2023
0:36
Promise of GPRC5D-targeted CAR-T therapies in multiple myeloma
Adam Sperling • 4 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals